Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, passed the on-site inspection by the U.S. FDA
I'm PortAI, I can summarize articles.
Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, underwent a CGMP on-site inspection by the U.S. FDA from March 4 to March 7, 2025, covering four major systems including the quality system for oral solid preparations and active pharmaceutical ingredients. Xinchang Pharmaceutical successfully passed the inspection, meeting the U.S. drug CGMP quality system requirements, and has received the FDA's on-site inspection report confirming the completion of the inspection
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments